دورية أكاديمية
Incomplete Plasmodium falciparum growth inhibition following piperaquine treatment translates into increased parasite viability in the in vitro parasite reduction ratio assay.
| العنوان: | Incomplete Plasmodium falciparum growth inhibition following piperaquine treatment translates into increased parasite viability in the in vitro parasite reduction ratio assay. |
|---|---|
| المؤلفون: | Walz A; Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.; University of Basel, Basel, Switzerland., Sax S; Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.; University of Basel, Basel, Switzerland., Scheurer C; Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.; University of Basel, Basel, Switzerland., Tamasi B; Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.; University of Basel, Basel, Switzerland., Mäser P; Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.; University of Basel, Basel, Switzerland., Wittlin S; Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.; University of Basel, Basel, Switzerland. |
| المصدر: | Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2024 Apr 30; Vol. 14, pp. 1396786. Date of Electronic Publication: 2024 Apr 30 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Media SA |
| مواضيع طبية MeSH: | Plasmodium falciparum*/drug effects , Plasmodium falciparum*/growth & development , Quinolines*/pharmacology , Antimalarials*/pharmacology , Drug Resistance* , Inhibitory Concentration 50* , Malaria, Falciparum*/drug therapy , Malaria, Falciparum*/parasitology, Humans ; Parasitic Sensitivity Tests ; Pilot Projects ; Artemisinins/pharmacology |
| مستخلص: | Antimalarial resistance to the first-line partner drug piperaquine (PPQ) threatens the effectiveness of artemisinin-based combination therapy. In vitro piperaquine resistance is characterized by incomplete growth inhibition, i.e. increased parasite growth at higher drug concentrations. However, the 50% inhibitory concentrations (IC Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Walz, Sax, Scheurer, Tamasi, Mäser and Wittlin.) |
| References: | J Infect Dis. 2017 Aug 15;216(4):468-476. (PMID: 28931241) Antimicrob Agents Chemother. 2013 Feb;57(2):818-26. (PMID: 23208711) PLoS Pathog. 2023 Jun 7;19(6):e1011436. (PMID: 37285379) Acta Trop. 1993 Dec;55(4):257-61. (PMID: 8147282) Antimicrob Agents Chemother. 2015 Oct;59(10):6428-36. (PMID: 26239987) Pharmaceuticals (Basel). 2023 Jan 23;16(2):. (PMID: 37009844) Malar J. 2012 Aug 22;11:292. (PMID: 22913649) Science. 2020 Jan 3;367(6473):51-59. (PMID: 31896710) N Engl J Med. 2014 Jul 31;371(5):484-5. (PMID: 25075853) BMC Med. 2015 Dec 22;13:305. (PMID: 26695060) J Stat Softw. 2017;76:. (PMID: 36568334) Lancet Infect Dis. 2013 Dec;13(12):1043-9. (PMID: 24035558) Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0055622. (PMID: 36197116) Nat Commun. 2018 Aug 17;9(1):3314. (PMID: 30115924) Antimicrob Agents Chemother. 2013 Nov;57(11):5277-83. (PMID: 23939897) Lancet Infect Dis. 2017 Feb;17(2):174-183. (PMID: 27818097) Antimicrob Agents Chemother. 2010 May;54(5):1872-7. (PMID: 20160056) Malar J. 2016 Oct 21;15(1):519. (PMID: 27769299) Trends Parasitol. 2021 Aug;37(8):709-721. (PMID: 34001441) PLoS One. 2012;7(2):e30949. (PMID: 22383983) Malar J. 2019 Dec 18;18(1):427. (PMID: 31849323) Antimicrob Agents Chemother. 2015 Feb;59(2):1110-8. (PMID: 25487796) mBio. 2017 May 9;8(3):. (PMID: 28487425) Lancet Infect Dis. 2019 Nov;19(11):1168-1169. (PMID: 31657776) Lancet Infect Dis. 2017 Feb;17(2):164-173. (PMID: 27818095) Exp Parasitol. 2007 Mar;115(3):296-300. (PMID: 17087929) Nature. 2014 Jan 2;505(7481):50-5. (PMID: 24352242) Lancet Infect Dis. 2022 Jun;22(6):760-761. (PMID: 35643094) Malar J. 2011 Sep 22;10:278. (PMID: 21939506) J Infect Dis. 2010 Nov 1;202(9):1362-8. (PMID: 20863228) Nat Commun. 2018 May 2;9(1):1769. (PMID: 29720620) J Med Chem. 2018 Oct 25;61(20):9371-9385. (PMID: 30256636) Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0011422. (PMID: 35727057) J Infect Dis. 2021 Jun 15;223(12):2154-2163. (PMID: 33119072) Antimicrob Agents Chemother. 2015 Dec 28;60(3):1896-8. (PMID: 26711753) |
| فهرسة مساهمة: | Keywords: 4-aminoquinoline; PRR assay; drug resistance; growth inhibition assay; parasite viability; piperaquine |
| تواريخ الأحداث: | Date Created: 20240515 Date Completed: 20240515 Latest Revision: 20240516 |
| رمز التحديث: | 20240516 |
| مُعرف محوري في PubMed: | PMC11091375 |
| DOI: | 10.3389/fcimb.2024.1396786 |
| PMID: | 38746786 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2235-2988 |
|---|---|
| DOI: | 10.3389/fcimb.2024.1396786 |